IDEXX Laboratories, Inc. Just Beat EPS By 9.0%: Here's What Analysts Think Will Happen Next

Shareholders will be ecstatic, with their stake up 22% over the past week following IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) latest quarterly results. IDEXX Laboratories reported US$1.2b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$4.01 beat expectations, being 9.0% higher than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the current consensus from IDEXX Laboratories' 13 analysts is for revenues of US$5.17b in 2027. This would reflect a decent 11% increase on its revenue over the past 12 months. Per-share earnings are expected to climb 11% to US$16.66. In the lead-up to this report, the analysts had been modelling revenues of US$5.14b and earnings per share (EPS) of US$16.66 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

View our latest analysis for IDEXX Laboratories

It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$709. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic IDEXX Laboratories analyst has a price target of US$810 per share, while the most pessimistic values it at US$470. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of IDEXX Laboratories'historical trends, as the 8.7% annualised revenue growth to the end of 2027 is roughly in line with the 7.7% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 7.5% annually. It's clear that while IDEXX Laboratories' revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at US$709, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple IDEXX Laboratories analysts - going out to 2028, and you can see them free on our platform here.

It might also be worth considering whether IDEXX Laboratories' debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.